# Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

> **NCT06041776** · PHASE3 · RECRUITING · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 570 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- EGFR Sensitive Mutation
- Adjuvant Therapy

## Interventions

- **DRUG:** Befotertinib + Icotinib placebo
- **DRUG:** Icotinib + Befotertinib placebo

## Key facts

- **NCT ID:** NCT06041776
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-28
- **Primary completion:** 2028-04-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 570 (ESTIMATED)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041776, "Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06041776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*